EMA recommends Merck heart drug

The European Medicines Agency has recommended Merck's drug Brinavess, or vernakalant, as a treatment for acute atrial fibrillation, or irregular heart beats, the London-based regulator said on Friday. Release | Report

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.